Thus, although TAMs and DCs express, respectively, the ICAM-1 binding CD18 integrins, CD11b (57) and CD11C (αxβ2) (61), their accumulation inside tumors did not require tumor-expressed ICAM-1, reflecting the potential usage by these cells of other Mac-1 and CD11C ligands expressed on cancer cells and in the TME including ECM components and proteoglycans (62, 63). Here, ICAM1 is linked to cancer.